A "taste" of what is to come: Reward sensitivity as a potential endophenotype for major depressive disorder

W. Kyle Simmons; Wayne C. Drevets

doi:10.1016/j.biopsych.2012.07.023

A "taste" of what is to come: Reward sensitivity as a potential endophenotype for major depressive disorder

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	526-527
Number of pages	2
Journal	Biological Psychiatry
Volume	72
Issue number	7
DOIs	https://doi.org/10.1016/j.biopsych.2012.07.023
State	Published - 1 Oct 2012
Externally published	Yes

Access to Document

10.1016/j.biopsych.2012.07.023

Cite this

@article{5407bda0fa454184ab982e6991b4013e,

title = "A {"}taste{"} of what is to come: Reward sensitivity as a potential endophenotype for major depressive disorder",

author = "Simmons, {W. Kyle} and Drevets, {Wayne C.}",

note = "Funding Information: Dr. Simmons' research is supported by National Institute of Mental Health Grant K01MH096175-01 , the Oklahoma Center for the Advancement for Science and Technology ( OCAST HR10-141 ), National Alliance for Research on Schizophrenia and Depression Young Investigator Award , and the Oklahoma Tobacco Research Center . Dr. Drevets' research is supported by the Oklahoma Center for the Advancement for Science and Technology (OCAST HR10-172) and the Stanley Foundation. Dr. Drevets is listed as coinventor on a use-patent for the use of scopolamine in major depression that has been filed by the U.S. government (through the National Institute of Mental Health). Dr. Drevets has consulted for Johnson and Johnson Pharmaceuticals, Inc., Eisai, Inc., and Myriad, Inc. and anticipates future compensation from Johnson & Johnson Pharmaceuticals.",

year = "2012",

month = oct,

day = "1",

doi = "10.1016/j.biopsych.2012.07.023",

language = "English",

volume = "72",

pages = "526--527",

journal = "Biological Psychiatry",

issn = "0006-3223",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - A "taste" of what is to come

T2 - Reward sensitivity as a potential endophenotype for major depressive disorder

AU - Simmons, W. Kyle

AU - Drevets, Wayne C.

N1 - Funding Information: Dr. Simmons' research is supported by National Institute of Mental Health Grant K01MH096175-01 , the Oklahoma Center for the Advancement for Science and Technology ( OCAST HR10-141 ), National Alliance for Research on Schizophrenia and Depression Young Investigator Award , and the Oklahoma Tobacco Research Center . Dr. Drevets' research is supported by the Oklahoma Center for the Advancement for Science and Technology (OCAST HR10-172) and the Stanley Foundation. Dr. Drevets is listed as coinventor on a use-patent for the use of scopolamine in major depression that has been filed by the U.S. government (through the National Institute of Mental Health). Dr. Drevets has consulted for Johnson and Johnson Pharmaceuticals, Inc., Eisai, Inc., and Myriad, Inc. and anticipates future compensation from Johnson & Johnson Pharmaceuticals.

PY - 2012/10/1

Y1 - 2012/10/1

UR - http://www.scopus.com/inward/record.url?scp=84866023874&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2012.07.023

DO - 10.1016/j.biopsych.2012.07.023

M3 - Comment/debate

C2 - 22959120

AN - SCOPUS:84866023874

SN - 0006-3223

VL - 72

SP - 526

EP - 527

JO - Biological Psychiatry

JF - Biological Psychiatry

IS - 7

ER -

A "taste" of what is to come: Reward sensitivity as a potential endophenotype for major depressive disorder

Access to Document

Other files and links

Cite this